title: High-dose methylprednisolone inhibits the OKT3-induced cytokine-related syndrome.
authors.forename: R
authors.initials: R
authors.lastname: Peces
authors.forename: J M
authors.initials: JM
authors.lastname: Urra
authors.forename: P
authors.initials: P
authors.lastname: Escalada
authors.forename: M
authors.initials: M
authors.lastname: Gorostidi
authors.forename: E
authors.initials: E
authors.lastname: González
authors.forename: C
authors.initials: C
authors.lastname: López-Larrea
mesh_terms: D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004417:Dyspnea / Q000139:chemically induced / Q000517:prevention & control*; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007022:Hypotension / Q000139:chemically induced / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000627:therapeutic use*; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D011654:Pulmonary Edema / Q000139:chemically induced / Q000517:prevention & control*; D013577:Syndrome
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D008775:Methylprednisolone